Radiation Oncology
Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.
Recent Discussions
Are you offering Lutathera for multiple recurrent meningiomas?
Lutathera is currently only FDA-approved for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, research is ongoing to explore its potential use for meningiomas, as many meningiomas express somatostatin receptors, which could make it a promising...
What dose constraints do you use for 60 Gy in 15-20 fraction lung treatments that are adjacent to the hilum?
The LUSTRE trial, which is a Canadian RCT comparing SABR (60/8, 48/4) vs. 60/15 provides some max point constraints to address this for 15#. Swaminath, Clin Lung Cancer. 2017 Mar;18(2):250-254. Spinal Canal 36 GyEsophagus 48 GyBrachial Plexus 50 GyHeart 66 GyGreat Vessels 66 GyTrachea/PBT 66 GySkin ...
What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?
There is no definitive evidence at this time that one of these imaging agents is clearly superior to the other because there are no comparative data in the same patient group.For Posluma, the potential benefit over Pylarify would be lower bladder excretion allowing for better visualization of the pe...
What is the optimal interval between vaginal cuff brachytherapy sessions?
At MD Anderson, we give 6 Gy x 5 to the surface and we most often treat every other day. However, given the low risk of toxicity, we think it's safe to make adjustments to this schedule. For example, we often do some treatments on sequential days if that's preferred for any reason. We also schedule ...
How do you manage a prostate cancer patient with pelvic lymphadenopathy and a single enlarged PSMA PET+ gastrohepatic node?
I would treat it as oligometastatic, starting with ADT/ARPI and use metastasis-directed therapy and pelvic radiation.
Are you offering hypofractionated comprehensive nodal irradiation following neoadjuvant chemotherapy for patients with locally advanced breast cancer in the setting of COVID-19?
In locally advanced breast cancer following neoadjuvant chemotherapy, we are offering hypofractionated radiation to the breast and regional nodes, and flat chest wall and regional nodes. In these cases, I treat to 40 Gy/15 fractions. For nodal coverage, I like to see 38 Gy line covering nodal basins...
Do you consider increased tumor thickness alone as an indication for postoperative radiation in oral cavity cancers?
Depth of invasion (DOI )has been shown to predict regional disease. As such, surgeons will use this information to decide if a neck dissection (ND) should be performed in the cN0 patient with oral tongue cancer.With no other adverse features (i.e., no PNI, no LVSI, no poor differentiation, good marg...
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
We typically try to wait as long as possible before we start WBRT. It depends on the burden and symptomatology of intracranial disease as well as the initial response to chemo-immunotherapy. If the brain metastases are asymptomatic and deemed OK to monitor closely (i.e., not likely to cause neurolog...
Would you treat a patient with an N2 ipsilateral recurrence following re-resection of bronchial stump recurrence?
My answer is predicated on the assumption that this patient has not had prior radiation therapy. If that is the case, then I would treat them. It is important to talk to the thoracic surgeon and know how the bronchial stump was "finished". My preference is that it is done with a fresh intercostal mu...
How do you counsel/advise patients when asked to compare ultrahypofractionated radiotherapy with the TULSA procedure?
I start by noting that the three NCCN-guideline recommended management plans for favorable-risk prostate cancer are radiotherapy (including SBRT), surgery, and active surveillance, and the latter two often require additional local therapy to render a patient cured within the next 5-10 years. In gene...